Inclusion of patients with acute leukemia in clinical trials: a prospective multicenter survey of 1066 cases

Annals of Oncology : Official Journal of the European Society for Medical Oncology
A DechartresV Lévy

Abstract

to estimate the prevalence of adults and children with acute leukemia (AL) included in clinical trials and to determine factors associated with noninclusion. all patients with AL admitted to the 17 departments managing AL in Paris area from 2005 to 2007 were prospectively included. Clinical data, therapeutic decisions, and enrollment in trials were recorded. Reasons that prevented accrual were identified. a total of 1066 admissions with AL (85% of adults) were recorded, and 34 trials were open. In adults, the rate of inclusion in a trial was 25% [95% confidence interval (CI) 21% to 28%] for acute myeloid leukemia (AML) and 23% (95% CI 17% to 29%) for acute lymphoid leukemia (ALL). In children, the rate of inclusion was 58% (95% CI 41% to 73%) for AML and 64% (95% CI 55% to 72%) for ALL. The rate of inclusion varied across centers, with a significant increase when they were involved in clinical research. Patients included in trials differed significantly from those not included according to age, primary/secondary AL, leukemia type, results of cytogenetic analyses, and stage of disease. the rate of inclusion is higher than in oncology. This difference may be explained by management in specialized centers often involved in clinica...Continue Reading

References

May 1, 1989·Archives of Disease in Childhood·C A Stiller, G J Draper
Jun 19, 1996·Journal of the National Cancer Institute·H A TejedaO W Brawley
Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L J FallowfieldR L Souhami
Sep 30, 1999·The New England Journal of Medicine·B LöwenbergA Burnett
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Warren B SaterenMichaele C Christian
Mar 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert L ComisEllen Stoval
Oct 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Catherine MengisMartin F Fey
Apr 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael S SimonDiane R Brown
Jun 10, 2004·JAMA : the Journal of the American Medical Association·Vivek H MurthyCary P Gross

❮ Previous
Next ❯

Citations

Apr 15, 2018·Cancer Medicine·Jessica L Krok-SchoenAshley E Rosko
Feb 5, 2019·Current Medical Research and Opinion·Bruno C MedeirosL Elise Horvath Walsh
Jan 7, 2016·Journal of Postgraduate Medicine·K Singh, S Mehta
Jul 22, 2019·The Oncologist·Florence Canouï-PoitrineSylvie Bastuji-Garin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.